Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.
About 10% of 100 clinical isolates of Enterococcus faecalis were resistant to greater than or equal to 25 micrograms of norfloxacin, ofloxacin, ciprofloxacin, and temafloxacin per ml. In this study, the DNA gyrase of E. faecalis was purified from a fluoroquinolone-susceptible strain (ATCC 19433) and two resistant isolates, MS16968 and MS16996. Strains MS16968 and MS16996 were 64- to 128-fold and 16- to 32-fold less susceptible, respectively, to fluoroquinolones than was ATCC 19433; MICs of nonquinolone antibacterial agents for these strains were almost equal. The DNA gyrase from ATCC 19433 had two subunits, designated A and B, with properties similar to those of DNA gyrase from other gram-positive bacteria such as Bacillus subtilis and Micrococcus luteus. Inhibition of the supercoiling activity of the enzyme from ATCC 19433 by the fluoroquinolones correlated with their antibacterial activities. In contrast, preparations of DNA gyrase from MS16968 and MS16996 were at least 30-fold less sensitive to inhibition of supercoiling by the fluoroquinolones than the gyrase from ATCC 19433 was. Experiments that combined heterologous gyrase subunits showed that the A subunit from either of the resistant isolates conferred resistance to fluoroquinolones. These findings indicate that an alteration in the gyrase A subunit is the major contributor to fluoroquinolone resistance in E. faecalis clinical isolates. A difference in drug uptake may also contribute to the level of fluoroquinolone resistance in these isolates.
Nakanishi
N
N
Episome Institute, Fujimimura, Gunma, Japan.
Yoshida
S
S
Wakebe
H
H
Inoue
M
M
Mitsuhashi
S
S
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002413:Cations, Divalent / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II / Q000302:isolation & purification; D004269:DNA, Bacterial / Q000096:biosynthesis; D004278:DNA, Superhelical / Q000096:biosynthesis; D004352:Drug Resistance, Microbial; D013293:Enterococcus faecalis / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000378:metabolism / Q000494:pharmacology
D000890:Anti-Infective Agents; D002413:Cations, Divalent; D004269:DNA, Bacterial; D004278:DNA, Superhelical; D000255:Adenosine Triphosphate; D004250:DNA Topoisomerases, Type II; D009643:Norfloxacin